In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OncoMed Pharmaceuticals Inc.

Division of Mereo BioPharma Group PLC
www.oncomed.com

Latest From OncoMed Pharmaceuticals Inc.

Finance Watch: Nkarta, Passage Bio Raise Venture Capital Mega-Rounds

Private Company Edition: Nkarta, Passage Bio and Achilles kicked off September with VC deals totaling more than $100m each. Also, Repare raised $82.5m and SutroVax won CARB-X cash.

Financing ImmunoOncology

Interview: Mereo All Set For Key Setrusumab Data

Although far from a one-product company, data in Q4 will be key to whether the brittle bone drug could become a blockbuster for the UK NASDAQ-listed biotech.

Strategy Orthopedics

Deal Watch: Sanofi Further Opts Out Of CNS Tie-Up With Voyager

Sanofi returns two partnered assets to Voyager, further unraveling 2015 deal. Celgene drops Mereo cancer candidate ahead of merger with Bristol, while Ultragenyx and Arcturus expand their joint rare disease efforts.

Business Strategies Commercial

Mereo Posts Early Upbeat Look At Brittle Bone Data For Setrusumab

The open-label Phase IIb data link setrusumab, licensed from Novartis, to improvements in bone density, offering encouragement for Mereo ahead of a critical upcoming readout for its lead program.

Clinical Trials Rare Diseases
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Mereo BioPharma Group PLC
  • Senior Management
  • John Lewicki, CEO
    Austin Gurney, PhD, SVP, Research & CSO
  • Contact Info
  • OncoMed Pharmaceuticals Inc.
    Phone: (650) 995-8200
    800 Chesapeake Dr.
    Redwood City, CA 94063
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register